Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including the nationâs leading ophthalmology pharmaceutical compounding business, ImprimisRx. The company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals and Radley Pharmaceuticals, companies founded as subsidiaries of Harrow Health. The Company also owns royalty rights in certain 505(b)(2) drug candidates being developed by Eton, Surface, Melt, Mayfield and Radley. Harrow intends to create, invest in and grow paradigm shifting health care businesses that put patients first. Source
No articles found.
Motif Bio is a clinical stage biopharmaceutical company developing novel antibioti...
Motif Bio is a clinical stage biopharmaceutical...
Founded in 2009, Clovis Oncology (NASDAQ: CLVS) is a commercial stage biotechnolog...
Founded in 2009, Clovis Oncology (NASDAQ: CLVS)...
Magellan Health, Inc., a Fortune 500 company, is a leader in managing the fastest ...
Magellan Health, Inc., a Fortune 500 company, i...
OncoSec Medical Incorporated is a clinical-stage biotechnology company focused on ...
OncoSec Medical Incorporated is a clinical-stag...
Eagle is a specialty pharmaceutical company working to advance safe and efficient ...
Eagle is a specialty pharmaceutical company wor...
Join the National Investor Network and get the latest information with your interests in mind.